---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-112016"
form_type: "8-K"
ticker: "NEUP"
cik: "0001191070"
company_name: "Neuphoria Therapeutics Inc."
filed_at: "2024-12-23T23:59:59+00:00"
generated_at: "2026-05-28T23:31:49.977836+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neuphoria completes redomiciliation from Australia to Delaware; shares to trade under NEUP

## Summary
- Effective Dec 23, 2024, Bionomics Ltd. became a wholly-owned subsidiary of Neuphoria; NEUP shares to trade on Nasdaq from Dec 24.
- Exchange ratio: 1 Neuphoria share per 2,160 Bionomics shares or per 12 ADSs; options and warrants converted proportionally.
- Board classified into three classes with staggered terms; Spyros Papapetropoulos CEO, Tim Cunningham CFO, Alan Fisher Chair.
- Neuphoria adopted 2024 Equity Incentive Plan and new anti-takeover charter provisions (classified board, 66 2/3% supermajority, no written consent).

## SEC filing metadata
- accession: 0001213900-24-112016
- form_type: 8-K
- ticker: NEUP
- cik: 0001191070
- company_name: Neuphoria Therapeutics Inc.
- filed_at: 2024-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.01, 3.02, 3.03, 5.03, 8.01, 5.01, 5.02, 5.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/ea0225663-8k_neupho.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-112016
- JSON: https://secwatch.observer/filing/0001213900-24-112016.json
- Plain text: https://secwatch.observer/filing/0001213900-24-112016.txt

## Key facts
- Governance Changes
  Neuphoria Therapeutics Inc.: Bylaws adopted in connection with redomiciliation.
  - Change: bylaw amendment
  source text: rights of our shareholders are no longer governed by Bionomics’ organizational documents and instead are now governed by Neuphoria’s Amended and Restated Certificate of Incorporation and its bylaws
  evidence_url: https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm
- Governance Changes
  Neuphoria Therapeutics Inc.: Amended and Restated Certificate of Incorporation adopted in connection with redomiciliation.
  - Change: charter amendment
  source text: rights of our shareholders are no longer governed by Bionomics’ organizational documents and instead are now governed by Neuphoria’s Amended and Restated Certificate of Incorporation
  evidence_url: https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm
- Governance Changes
  Neuphoria Therapeutics Inc.: Code of Conduct adopted, applies to all directors, officers and employees.
  - Change: code of ethics
  source text: Neuphoria has adopted a Code of Conduct (the “Code”), which applies to all directors, officers and employees
  evidence_url: https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm
- M&A Transactions
  Neuphoria Therapeutics Inc. underwent a change of control involving Neuphoria Therapeutics Inc. (closed 2024-12-23).
  - Action: change of control
  - Counterparty: Neuphoria Therapeutics Inc.
  - Closing: 2024-12-23
  source text: On December 23, 2024 US time (“Effective Date”), the redomiciliation (“Redomiciliation”) of Bionomics Limited, an Australian corporation (“Bionomics”), was implemented under Australian law in accordance with a Scheme Implementation Agreement (as amended) between Bionomics and Neuphoria Therapeutics Inc., a Delaware corporation (“Neuphoria”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.